Survival following reirradiation using intensity-modulated radiation therapy with temozolomide in selected patients with recurrent high grade gliomas

Basit Öğe Kaydı
dc.contributor.authorAktan, Meryem
dc.contributor.authorKoc, Mehmet
dc.contributor.authorKanyilmaz, Gul
dc.date.accessioned2024-02-23T14:37:37Z
dc.date.available2024-02-23T14:37:37Z
dc.date.issued2015
dc.departmentNEÜen_US
dc.description.abstractBackground: High grade gliomas often recur after initial treatment. Despite so many treatment options, there is no standard treatment for recurrent gliomas. The aim of this study is to offer survival following reirradiation (re-RT) using intensity-modulated radiation therapy (IMRT) with temozolomide in selected patients with recurrent high grade gliomas. Methods: We examined the medical records of 21 adult patients with recurrent high grade gliomas who were reirradiated with IMRT at the time of tumor recurrence or progression. Tumor recurrence was shown by gadolinium-enhanced magnetic resonance imaging (MRI) and diagnosis was established by pathology review. Statistical analyses were performed with SPSS version 18.0.1 using Cox regression analyses, log-rank test and Kaplan-Meier method. Results: Eighteen patients presented by localized recurrence, three patients with diffuse recurrence. Median radiotherapy (RT) dose was 54 Gy. About 81% patients received temozolomide with re-RT. The time interval between two courses RT was median 39.3 months (range, 9.6-140.8 months). The response was checked by MRI. About 24% patients achieved complete response (CR) and 29% patient partial response (PR). Stable disease (SD) was observed in 47% patients. Median follow-up time from diagnosis was 41.4 months (range, 16.6-145.4 months) and 12.3 months (range, 2-27.6 months) from re-RT. Median time to recurrence was 39.3 months (range, 9.6-140.8 months). Median survival after re-RT was 18 months for anaplastic astrocytoma (AA), 14.1 months for glioblastoma multiforme (GBM) (range, 11-17.2 months) (P=0.1) and 7.1 months for patients with Karnofsky performance status (KPS) <70 before re-RT and 17.4 months for KPS >70 (P=0.02). Conclusions: re-RT is one of the treatment options for recurrent high grade gliomas and IMRT can be an effective treatment modality for recurrent high grade brain tumors with only mild side effects. Survival is better in patients with good performance status and in recurrent anaplastic tumors after re-RT.en_US
dc.identifier.doi10.3978/j.issn.2305-5839.2015.11.29
dc.identifier.issn2305-5839
dc.identifier.issn2305-5847
dc.identifier.issue20en_US
dc.identifier.pmid26697464en_US
dc.identifier.scopus2-s2.0-85015483512en_US
dc.identifier.urihttps://doi.org/10.3978/j.issn.2305-5839.2015.11.29
dc.identifier.urihttps://hdl.handle.net/20.500.12452/16150
dc.identifier.volume3en_US
dc.identifier.wosWOS:000421425100003en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherAme Publ Coen_US
dc.relation.ispartofAnnals Of Translational Medicineen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectGliomaen_US
dc.subjectGlioblastomaen_US
dc.subjectIntensity Modulated Radiotherapyen_US
dc.subjectReirradiation (Re-Rt)en_US
dc.subjectSurvivalen_US
dc.titleSurvival following reirradiation using intensity-modulated radiation therapy with temozolomide in selected patients with recurrent high grade gliomasen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu